Summary:
- The article discusses the development of a new drug candidate by Glenmark Pharmaceuticals for the treatment of diabetic nephropathy, a serious complication of diabetes that can lead to kidney failure.
- The drug candidate, GRC 27864, is a selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ) and has shown promising results in preclinical studies, demonstrating potential to improve kidney function and reduce inflammation in diabetic nephropathy.
- Glenmark Pharmaceuticals is currently conducting a Phase 2 clinical trial to evaluate the safety and efficacy of GRC 27864 in patients with diabetic nephropathy, with the goal of advancing the drug candidate towards regulatory approval and commercialization.